PCR93 Comprehensibility and Usability of an Electronic COVID-19 Daily Symptom Diary

Abstract

Symptoms of COVID-19 are heterogeneous across individuals and can range from mild to severe. Labcorp Drug Development (LDD) created an electronic COVID-19 Daily Symptom Diary, in accordance with FDA guidance, to assess frequency and severity of COVID-19 symptoms in adult individuals with mild to moderate disease severity for use as an endpoint measure in outpatient clinical trials of treatments for COVID-19. This study evaluated how participants who have previously contracted COVID-19 completed, understood, and interacted with the electronic COVID-19 Daily Symptom Diary.